Dipyridamole

Dipyridamole is an orally active phosphodiesterase (PDE) inhibitor. Dipyridamole also is an antiplatelet agent used in secondary prophylaxis against stroke. Dipyridamole can induce cancer cell-specific apoptosis[1][2][3].

Product Specifications

CAS Number

[58-32-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Dipyridamole.html

Purity

99.93

Solubility

DMSO : ≥ 50 mg/mL|H2O : < 0.1 mg/mL

Smiles

OCCN(CCO)C1=NC(N2CCCCC2)=C(N=C(N(CCO)CCO)N=C3N4CCCCC4)C3=N1

Molecular Formula

C24H40N8O4

Molecular Weight

504.63

Precautions

H302, H315, H319, H335

References & Citations

[1]Kerndt CC, Nagalli S. Dipyridamole. 2021 Nov 25. In: StatPearls [Internet]. Treasure Island (FL) : StatPearls Publishing; 2022 Jan–. PMID: 32119342.|[2]Longo, Joseph, etal. Cyclic AMP-hydrolyzing phosphodiesterase inhibitors potentiate statin-induced cancer cell death. Molecular oncology vol. 14,10 (2020) : 2533-2545|[3]Wang, Jiaan-Der, etal. Exosomal HMGB1 Promoted Cancer Malignancy. Cancers vol. 13,4 877. 19 Feb. 2021.